摘要
硼替佐米是新型靶向治疗的抗肿瘤药物,于2003年被美国FDA批准用于多发性骨髓瘤(MM)的治疗。多项临床研究表明周围神经病变(peripheralneuropathy,PN)是硼替佐米主要的剂量限制性不良反应,影响患者的生存质量及疗效。在硼替佐米治疗的最大群体研究中,SUMMIT和CREST的Ⅱ期临床试验及APEX和VISTA的Ⅲ期临床试验结果表明,
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2012年第2期157-159,共3页
Chinese Journal of Hematology
参考文献21
-
1Richardson PG,Sonneveld P,Schuster M,et al.Extended followup of a phase 3 trial in relapsed multiple myeloma:final time-toevent results of the APEX trial.Blood,2007,110:3557-3560.
-
2Argyriou AA,Iconomou G,Kalofonos HP.Bortezomib-induced peripheral neuropathy in multiple myeloma:a comprehensive review of the literature.Blood,2008,112:1593-1599.
-
3Prommer EE.Topical analgesic combinations for bortezomib neuropathy.J Pain Symptom Manage,2009,37:e3-5.
-
4Richardson PG,Sonneveld P,SchusterMW,et al.Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase Ⅲ APEX trial in relapsed multiple myeloma:impact of a dose-modification guideline.Br J Haematol,2009,144:895-903.
-
5Ravaglia S,Corso A,Piccolo G,et al.Immune-mediated neuropathies in myeloma patients treated with bortezomib.Clin Neurophysiol,2008,119:2507-2512.
-
6Poruchynsky MS,Sackett DL,Robey RW,et al.Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells:a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.Cell Cycle,2008,7:940-949.
-
7Csizmadia V,Raczynski A,Csizmadia E,et al.Effect of an experimental proteasome inhibitor on the cytoskeleton,cytosolic protein turnover,and induction in the neuronal cells in vitro.Neurotoxicology,2008,29:232-243.
-
8Shin YK,Jang SY,Lee HK,et al.Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomibinduced peripheral neuropathy.Glia,2010,58:1961-1976.
-
9王洪涛,刘卓刚,杨威,廖爱军,张嵘,吴斌,王慧涵,姚鲲,李迎春.硼替佐米致周围神经病变的机制及还原型谷胱甘肽逆转神经毒性的研究[J].中华血液学杂志,2011,32(2):107-111. 被引量:10
-
10Durrant D,Liu J,Yang HS,et al.The bortezomib-induced mitochondrial damage is mediated by accumulation of active protein kinase C-delta.Biochem Biophys Res Commun,2004,321:905-908.
二级参考文献10
-
1Andreas AA,Gregoris I,Haralabos PK.Bortezomib-induced peripheral neuropathy in multiple myeloma:a comprehensive review of the literature.Blood,2008,112:1593-1599.
-
2Ocean AJ,Vahdat LT.Chemotherapy-induced peripheral neuropathy:pathogenesis and emerging therapies.Support Care Cancer,2004,12:619-625.
-
3Cavaletti G,Gilardini A,Canta A,et al.Bortezomib induced peripheral neurotoxicity:a neurophysiological and pathological study in the rat.Exp Neurol,2007,204:317-325.
-
4Cavaletti G,Tredici G,Marmiroli P,et al.Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats.Acta Neuropathol,1992,84:364-371.
-
5McDonald ES,Randon KR,Knight A,et al.Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo:a potential mechanism for neurotoxicity.Neurobio Dis,2005,18:305-313.
-
6Kikuchi S,Shinpo K,Tsuji S,et al.Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons.Brain Res,2003,964:228-236.
-
7Richardson PG,Sonneveld P,Schuster MW,et al.Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.Engl J Med,2005,352:2487-2498.
-
8Pei XY,Dai Y,Grant S.Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.Clin Cancer Res,2004,10:3839-3852.
-
9Qin JZ,Ziffra J,Stennett L,et al.Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.Cancer Res,2005,65:6282-6293.
-
10Landowski TH,Megli CJ,Nullmeyer KD,et al.Mitochondrialmediated disregulation of Ca^2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.Cancer Res,2005,65:3828-3836.
共引文献9
-
1林志敏,陈沁园,王微,程纬民.电针治疗多发性骨髓瘤化疗性周围神经病变的研究进展[J].世界最新医学信息文摘,2020(32):61-62.
-
2黄瑞霞,李鑫,孙振昌,张蕾,李玲,王新华,张明智.谷胱甘肽预防恶性淋巴瘤长春新碱化疗所致神经毒性的临床研究[J].中国肿瘤临床,2011,38(23):1468-1470. 被引量:10
-
3韩秀华,孙丽华,邹健,孟亚红,范小红,王雪莲.还原型谷胱甘肽对多发性骨髓瘤患者沙利度胺相关的周围神经病变的保护作用[J].临床荟萃,2014,29(4):410-413. 被引量:6
-
4郭丽丽,刘红,林赠华.中药“神经方”对硼替佐米所致周围神经病变治疗作用的实验研究[J].中华血液学杂志,2015,36(9):796-798. 被引量:6
-
5唐晓霞,周泽平,余景星,陶伟,毕慧,邹顺.硼替佐米致周围神经病变的防治进展[J].实用药物与临床,2018,21(2):231-235. 被引量:8
-
6韩秀华,赵兰,张飞飞,屈蓓蓓,何滔滔.还原型谷胱甘肽预防沙利度胺治疗相关周围神经病变的临床研究[J].白血病.淋巴瘤,2018,27(6):340-343. 被引量:2
-
7王洪涛,李诗文,李佳,刘卓刚.硼替佐米致周围神经病变27例临床分析[J].现代肿瘤医学,2018,26(23):3846-3849. 被引量:2
-
8李仙仙,杨建斌,王怀昌,张海燕.电针治疗硼替佐米致周围神经病变的疗效观察[J].长治医学院学报,2019,33(4):289-291. 被引量:4
-
9任咏惠,李丽,汪梅,王阔,李洁.硼替佐米致多发性骨髓瘤患者周围神经病变的研究进展[J].临床医学研究与实践,2022,7(4):196-198. 被引量:9
同被引文献23
-
1亢卉.硼替佐米在恶性血液病中的作用机制[J].中国新药与临床杂志,2006,25(6):459-462. 被引量:9
-
2MEISTER S,SCHUBERT U,NEUBERT K,et al.Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition[J].Cancer Res,2007,67(4):1783-1792.
-
3ROSINOL L,MONTOTO S,CIBEIRA MT,et al.Bortezomibinduced severe hepatitis in multiple myeloma:a case report[J].Arch Intern Med,2005,165(4):464-465.
-
4PLASMATI R,PASTORELLI F,CAVO M,et al.Neuropathy in multiple myeloma treated with thalidomide:a prospective study[J].Neurology,2007,69(6):573-581.
-
5RICHARDSON PG,XIE W,MITSIADES C,et al.Single-agent bortezomib in previously untreated multiple myeloma:efficacy,characterization of peripheral neuropathy,and molecular correlations with response and neuropathy[J].J Clin Oncol,2009,27(21):3518-3525.
-
6MORAWSKA M,GRZASKO N,KOSTYRA M,et al.Therapyrelated peripheral neuropathy in multiple myeloma patients[J].Hematol Oncol,2015,33(4):113-119.
-
7RICHARDSON PG,BARLOGIE B,BERENSON J,et al.A phase 2 study of bortezomib in relapsed,refractory myeloma[J].N Engl J Med,2003,348(26):2609-2617.
-
8JAGANNATH S,BARLOGIE B,BERENSON J,et al.A phase2 study of two doses of bortezomib in relapsed or refractory myeloma[J].Br J Haematol,2004,127(2):165-172.
-
9RICHARDSON PG,SONNEVELD P,SCHUSTER M,et al.Extended follow-up of a phase 3 trial in relapsed of the APEX trial[J].Blood,2007,110(10):3557-3560.
-
10MOREAU P,PYLYPENKO H,GROSICKI S,et al.Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma:a randomized,phase 3,non inferiority study[J].Lancet Oncol,2011,12(5):431-440.
引证文献3
-
1夏凡,马晶晶,包健安.硼替佐米致周围神经病变和急性心衰1例并文献复习[J].中国新药与临床杂志,2016,35(2):148-150. 被引量:3
-
2张丽丽,王一浩,邵宗鸿,马骏.大剂量静脉输注甲钴胺预防硼体佐米治疗诱发的多发性骨髓瘤患者周围神经病的效果[J].中国实验血液学杂志,2017,25(2):480-484. 被引量:8
-
3史月,薛慧,高峰,冯术青.多发性骨髓瘤硼替佐米治疗后以肠梗阻为首发症状的周围神经病变2例[J].临床肿瘤学杂志,2020,25(4):378-380. 被引量:5
二级引证文献16
-
1吴蕾.2型糖尿病周围神经病变患者使用甲钴铵注射液治疗的临床效果[J].世界最新医学信息文摘,2019,0(79):115-115. 被引量:1
-
2侯伟华,朱妍,张真稳,陈晖.糖尿病周围神经病变合并POEMS综合征1例[J].临床心身疾病杂志,2019,25(1):179-180. 被引量:1
-
3程军,汪龙,朱玲娜.14例硼替佐米致心力衰竭文献分析[J].中国医院药学杂志,2017,37(11):1089-1091. 被引量:2
-
4唐晓霞,周泽平,余景星,陶伟,毕慧,邹顺.硼替佐米致周围神经病变的防治进展[J].实用药物与临床,2018,21(2):231-235. 被引量:8
-
5王洪涛,李诗文,李佳,刘卓刚.硼替佐米致周围神经病变27例临床分析[J].现代肿瘤医学,2018,26(23):3846-3849. 被引量:2
-
6刘永华,江锦红,章俏雷,金伟媚,兰义芬,周泽平,方炳木.“补肾活血”法预防硼替佐米治疗多发性骨髓瘤致周围神经病变的疗效观察[J].中华全科医学,2020,18(3):374-376. 被引量:13
-
7吕鹏,云莎,徐慧霞,乔蓉,徐海芹,李丽梅.硼替佐米治疗多发性骨髓瘤致心律失常2例并文献复习[J].中华养生保健,2020,38(7):194-195.
-
8张珠儿,林秋英,张秀珍.聚焦解决护理模式对硼替佐米治疗多发性骨髓瘤过程中周围神经病变的影响[J].中外医学研究,2020,18(29):111-113.
-
9杨瑛,佘笑梅,丘立丹,练诗梅.以硼替佐米为基础的化疗治疗多发性骨髓瘤的疗效与安全性[J].癌症进展,2020,18(21):2228-2230. 被引量:9
-
10张新莲,孙云霞,牛宇娟,张鹏鹏.多发性骨髓瘤相关周围神经病变治疗进展[J].甘肃医药,2020,39(11):976-979. 被引量:6
-
1任荣.硫辛酸联合甲钴胺治疗糖尿病周围神经病变30例疗效观察[J].山西医药杂志(下半月),2013,42(11):1286-1287.
-
2李光伟,向红丁.胰岛素/血糖比值在群体研究中作为胰岛β细胞功能指数的可能性和局限性[J].中国实验诊断学,1998,2(1):15-16. 被引量:3
-
3王春勇,刘雅文,于亚琴,何钟勤,韩岁梅.老年健康与可溶性白细胞介素2受体关系的研究[J].中国公共卫生学报,1996,15(5):307-308.
-
4庞韩英.奥曲肽联合法莫替丁治疗EVH35例[J].山东医药,2006,46(17):63-63. 被引量:2
-
5张建伟,文磊.依帕司他联合甲钴胺治疗糖尿病周围神经病变疗效观察[J].云南医药,2013,34(4):319-321. 被引量:5
-
6多发性骨髓瘤周围神经病变诊疗中国专家共识(2015年)[J].中华内科杂志,2015,54(9):821-824. 被引量:45
-
7涂海燕,刘安文.血浆内皮素-1与放射性肺损伤的相关性研究进展[J].实用癌症杂志,2008,23(3):324-326. 被引量:2
-
8何亚乐.超声心动图对可疑心内膜炎的诊断价值[J].岭南心血管病杂志,1996,2(3):38-38.
-
9谭琛.起源于左心室summit室性心律失常的基质及心外膜消融进展[J].心血管病学进展,2017,38(1):12-14. 被引量:1
-
10Foster J.K.,Kolm P.,杜媛.成功置入冠状动脉支架的患者应用西洛他唑治疗可以降低6个月资源占用和成本:来自西洛他唑治疗再狭窄(CREST)试验的结果[J].世界核心医学期刊文摘(心脏病学分册),2007,0(2):23-23. 被引量:1